Introduction
IL-1β is one of the most powerful pro-inflammatory cytokines; it affects virtually every organ, and several human pathologies are primarily driven by unrestrained IL-1β production. Over production contributes to pathophysiological changes seen in diseases such as rheumatoid arthritis, neuropathic pain, inflammatory bowel disease, osteoarthritis, vascular disease, multiple sclerosis, Alzheimer's disease, and cancer (Dinarello 1996; Braddock and Quinn 2004; Dinarello 2004; Coussens and Werb 2002) . IL-1β exerts its protective action against infections by activating several responses including the rapid recruitment of neutrophils to inflammatory sites, activation of the endothelial adhesion molecules, induction of cytokines and chemokines, and the stimulation of adaptive immunity. (Sahoo et al. 2011) . IL-1β is produced by several different categories of immune cells including monocytes (Shi and Pamer 2011) , T cells (Numerof et al. 1990) , and natural killer (NK) cells (DeSanctis et al. 1997) . IL-1β is secreted in response to immune cell recognition of pathogen-associated molecular patterns (PAMPs) through pattern recognition receptors (PRR) (Gaestel et al. 2009 ). Pro IL-1β matures to IL-1β by interacting with the protease, caspase 1 (Lopez-Castejon and Brough 2011; Swaan et al. 2001; Dinarello 1996) . Caspase 1 is activated by an intracellular multiprotein complex referred to as the inflammasome. It cleaves the 31 kD pro IL-1β to the mature 17 kD form leading to its secretion (Church et al. 2008; Franchi et al. 2009; Lopez-Castejon and Brough 2011; Martinon and Tschopp Abstract Pentachlorophenol (PCP) and Dichlorodiphenyltrichloroethane (DDT) are environmental contaminants found in human blood. Previous studies have shown that PCP and DDT inhibit the lytic function of highly purified human natural killer (NK) lymphocytes and decrease the expression of several surface proteins on NK cells. Interleukin-1 βeta (IL-1β) is a cytokine produced by lymphocytes and monocytes, and anything that elevates its levels inappropriately can lead to chronic inflammation, which among other consequences can increase tumor development and invasiveness. Here, PCP and DDT were examined for their ability to alter secretion of IL-1β from immune cell preparations of various complexity: NK cells; monocyte-depleted (MD) peripheral blood mononuclear cells (PBMCS); and PBMCs. Cells were exposed to concentrations of PCP ranging from 5 to 0.05 µM and DDT concentrations of 2.5-0.025 μM for 24, 48 h, and 6 days. Results showed that both PCP and DDT increased IL-1β secretion from all of the immune cell preparations. The specific concentrations of PCP and DDT that increased IL-1β secretion varied by donor. Immune cells from all donors showed compound-induced increases in IL-1β secretion at one or more concentration at one or more length of exposure. The mechanism of PCP stimulation of IL1-β secretion was also addressed, and it appears that the MAPKs, ERK1/2 and p38, may be utilized by PCP to stimulate secretion of IL-1β. 2007 ). A favorable environment for angiogenesis and metastasis results when chronic inflammation provides an abundant source of growth factors, cytokines, chemokines, prostaglandins, and reactive oxygen species (Balkwill and Mantovani 2001; Coussens and Werb 2002) . Inflammation and dysregulation in immune cells could be caused by exposure to environmental contaminants that are found in human blood.
Pentachlorophenol (PCP) is an organochlorine compound that contaminates the environment due to its various uses (ATSDR 2001; Cirelli 1978; Brown et al. 2005) . PCP has been used as a fungicide, insecticide, herbicide, in antifouling paint, and as a wood preservative (Cirelli 1978) . It has been found in human blood with serum levels ranging from 0.26 to 5 μM in individuals who live in PCP-treated log homes (Cline et al. 1989) . Levels averaging 0.15 μM were found in the serum of individuals with no known exposure (Cline et al. 1989; Uhl et al. 1986 ). PCP exposure is associated with cancers of the blood (lymphoma and myeloma) and kidney (Demers et al. 2006; Cooper and Jones 2008) . Cytotoxic and gene expression effects of PCP in human liver and bladder cells were investigated by Wang et al. (2000) . Liver cells were more resistant to the toxicity of PCP than were bladder cells and expression of cellular apoptosis susceptibility protein (CAS) decreased in cells after treatment with PCP.
4, 4′-Dichlorodiphenyltrichloroethane (DDT) was extensively used as an agricultural pesticide throughout the world (CDC 2003 (CDC , 2005 Geisz et al. 2008; Turusov et al. 2002; Loganathan 2012) . While it has been banned in many countries including the USA, it is still used in other countries primarily to control mosquitos (CDC 2003 (CDC , 2005 . Despite its ban, DDT has been found in human bodily fluid and has been detected in measurable concentrations in blood samples within US population (Thornton et al. 2002; Patterson et al. 2009 ). In countries such as Mexico where DDT is still used, it has been found in serum with concentrations as high as 23,169 ng/g of lipid (approximately 260 nM) (Koepke et al. 2004; Trejo-Acevedo et al. 2009 ). An association between blood levels of DDT and decreased numbers of NK cells as well as decreased NK function has been reported (Svensson et al. 1994; Eskenazi et al. 2009 ).
Results of prior ex vivo studies indicate that exposure of human NK cells to both PCP and DDT causes inhibition of their ability to bind and lyse tumor target cells (Reed et al. 2004; Nnodu and Whalen 2008; Udoji et al. 2010; Hurd et al. 2012; Hurd-Brown et al. 2013) . Both compounds also decrease the expression of certain cell-surface proteins needed for NK lymphocytes to bind to tumor targets (Hurd et al. 2012; Hurd-Brown et al. 2013) . Dysregulation in secretion of NK-stimulatory ILs (IL-2, IL-12 and/or IL-10) and NK-inhibitory cytokine, IL-4 has been reported after exposure to PCP and DDT (Beach and Whalen 2006) . Based on the results from previous studies on the effects of PCP and DDT on immune function and the importance of IL-1β as a master regulator of immune response and inflammation, we hypothesize that PCP and DDT may alter the secretion of IL-1β from human immune cells.
In this study, preparations of immune cells with increasing complexity were utilized to investigate the effects of ex vivo exposures to PCP and DDT on the secretion of IL-1β. Human NK cells, human monocyte-depleted (MD) peripheral blood mononuclear cells (PBMCs) (MD-PBMCs), and PBMCs were each exposed to the compounds, and secreted IL-1β levels were assessed. Monitoring exposure to PCP and DDT on these increasingly reconstituted preparations of immune cells allows us to see whether the effects of the compounds are dependent on the nature of the cell preparation. An additional goal of this study was to investigate the mechanism of any compound-induced increases in IL-1β secretion. Thus, additional studies were done where PBMCs were pre-treated with Caspase-1 inhibitor, p44/42 (ERK 1/2) pathway inhibitor, JNK pathway inhibitor, p38 inhibitor, or NFĸB inhibitor before exposure to the compounds.
Materials and methods

Preparation of PBMCs, and monocyte depletionPBMCs
PBMCs were isolated from leukocyte filters (PALL-RCPL or FLEX) obtained from the Red Cross Blood Bank (Nashville, TN) as described in (Meyer et al. 2005) . Leukocytes were obtained from the filters by back-flushing the filters with an elution medium which contains (sterile phosphatebuffered saline (PBS) containing 5 mM disodium EDTA and 2.5 % [w/v] sucrose) and then collecting the eluent. The eluent was layered onto LymphoSep cell separation medium (1.077 g/mL) (MP Biomedicals, Irvine, CA) and centrifuged at 1200 g for 30-50 min. Following centrifuging and washing, the cells were layered on bovine calf serum for platelet removal. The cells were then suspended in RPMI-1640 complete medium which consisted of RPMI-1640 supplemented with 10 % heat-inactivated BCS, 2 mM l-glutamine, and 50 U penicillin G with 50-µg streptomycin/mL Monocyte-depleted (MD) PBMCs (10-20 % CD16 
Preparation of NK cells
NK cells were isolated from buffy coats (source leukocytes from healthy adult donors) purchased from Key Biologics, LLC (Memphis, TN) using a rosetting procedure. RosetteSep human NK cell enrichment antibody cocktail 1 3 (0.6-0.8 mL) (StemCell Technologies, Vancouver, British Columbia, Canada) was added to 45 mL of the buffy coat. The mixture was incubated for 20 min at room temperature (~25 °C). Eight milliliters of the mixture was layered onto 4 mL of LymphoSep (1.077 g/mL) and centrifuged at 1200g for 30-50 min. The NK cells were collected and washed twice with phosphate-buffered saline (PBS) pH 7.4 and stored in complete media (RPMI-1640 supplemented with 10 % heat-inactivated bovine calf serum (BCS), 2 mM l-glutamine, and 50 U penicillin G with 50 µg streptomycin/ml) at 1 million cells/mL at 37 °C and air/CO 2 , 19:1.
Chemical preparation
DDT and PCP were purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions were prepared as 100 mM solutions in Dimethylsulfoxide (DMSO). Desired concentrations of either DDT or PCP were prepared by dilution of the desired stock into cell culture media.
Inhibitor preparation
Enzyme inhibitors were purchased from Fisher Scientific (Pittsburgh, PA).The stock solution for each inhibitor was a 50 mM solution in dimethylsulfoxide (DMSO). Capase-1 inhibitor II, MEK 1/2 pathway inhibitor (PD98059), p38 inhibitor (SB202190), JNK inhibitor (B178D3), and NFκB inhibitor (BAY11-7085) were prepared by dilution of the stock solution into cell culture media.
Cell treatments
PBMCs, MD-PBMCs, and NK cells (at a concentration of 1.5 million cells/mL) were treated with PCP (0.05-5 µM) and appropriate control for 24, 48 h, and 6 days. Additionally, each of the above types of cell preparations were treated with DDT (0.025-2.5 µM) and appropriate control for 24, 48 h, and 6 days. Once the incubation period was complete, the cells were pelleted and supernatants were obtained and stored at −70 °C until assaying for IL-1β. For the pathway inhibitor experiments, PBMCs were treated with enzyme inhibitors 1 h prior to adding PCP at concentrations of 5, 2.5, and 1 µM for 24 h. After the cells were incubated, the cells were pelleted and supernatants were obtained and stored at −70 °C until assaying for IL-1β.
Cell viability
Cell viability was measured at the end of the 24-h, 48-h and 6-day exposure period. Viability was determined using the trypan blue exclusion method .Cells were mixed with trypan blue and counted using a hemocytometer. The total number of cells and the number of dead were counted for both control and treated cells to determine the percent viable cells.
IL-1β secretion assay
IL-1β levels were measured using the BD OptEIA™ Human IL-1β enzyme-linked immunosorbent assay (ELISA) kit (BD-Pharmingen, San Diego, CA). A 96-well micro well plate, designed for ELISA assays (Fisher, Pittsburgh, PA), was coated with a capture antibody for IL-1β that was diluted in coating buffer. The ELISA plate was incubated with the capture antibody overnight at 4 °C. After the incubation, the capture antibody was removed, and blocking solution (PBS and bovine calf serum) was added to each well and incubated at room temperature for 1 h. Following the blocking step, cell supernatants and IL-1β standards were added and incubated for 2 h at room temperature. Detection antibody linked to horseradish peroxidase (HRP) was then added followed by substrate. The reaction was stopped by addition of 1 M phosphoric acid, and absorbance was measured at 450 nm on a Thermo Labsystems Multiskan MCC/340 plate reader (Fisher Scientific).
Statistical analysis
Data were analyzed using ANOVA and the Student's t test. Data were initially compared within a given experimental setup by ANOVA. A significant ANOVA was followed by pair wise analysis of control versus exposed data using Student's t test, a p value of less than 0.05 was considered significant.
Results
Viability of NK cells, MD-PBMCs, and PBMCs exposed to PCP
Exposures to PCP (0.05-5 µM) for 24 and 48 h had no effect on the viability of NK cells, MD-PBMCs, and PBMCs. Exposures of NK cells and PBMCs to these same concentrations of PCP for 6 d also caused no decreases in viability when compared to control cells (data not shown). However, MD-PBMCs showed a small but significant decrease in viability with exposures to 1 μM (13 % decrease) and 5 μM PCP (7 % decrease) after 6 days.
Viability of NK cells, MD-PBMCs, and PBMCs exposed to DDT
Exposure of NK cells, MD-PBMCs, and PBMCs to 0.025-2.5 µM DDT for 24, 48 h, or 6 d produced no significant decreases in cell viability as compared to the control (data not shown).
Viability of PBMCs treated with selective enzyme inhibitors and then exposed to PCP
PBMCs pre-treated for 1 h with selected signaling pathway inhibitors followed by exposure to 1, 2.5, or 5 µM PCP for 24 h were also examined for viability. There were no significant changes in the viability of these cells compared to appropriate controls with any of the inhibitors (data not shown). Table 1 shows the effects on IL-1β secretion by NK cells exposed to 0, 0.05, 0.1, 0.25, 0.5, 1, 2.5, and 5 µM PCP for 24, 48 h, and 6 days. Cells from four donors were tested. IL-1β secretion from NK cells of donor KB188 (KB = Key Biologic buffy coat) was increased by 1.3-fold when the cells were exposed to 2.5 µM PCP for 24 h (p < 0.05). IL-1β secretion was not significantly increased at this same concentration in cells from the other three donors and was significantly decreased at the 5 μM exposure after 24 h. Forty-eight-hour exposures to one or more concentration of PCP caused increases in IL-1β secretion in cells from three of the four donors (KB188, 192, 194) . NK cells from donor KB196 showed increased secretion of IL-β with 0.05 and 0.1 µM exposures to PCP after 6 days. Thus, all donor NK cells showed increased secretion of IL-1β after exposure to PCP; however, the concentrations and lengths of exposure at which these increases occurred varied among the donors. 
Effects of PCP exposures on secretion of IL-1β by NK cells
Effects of PCP exposures on secretion of IL-1β by MD-PBMCs
The effects of exposures to PCP on secretion of IL-1β from MD-PBMCs after 24, 48 h, and 6 d from four donors (F = filter obtained from the Red Cross) are shown in Table 2 . This preparation consists mainly of NK cells and T cells. When MD-PBMCs were exposed to PCP for 24 h, there were statistically significant increases in IL-1β secretion at the 5 µM concentration of PCP for all donors. The fold increases were 1.7-fold for F209, 1.8-fold for F239, 2.5-fold for F241, and twofold for F243 when compared to the control. All but one of the donors showed increased secretion at other concentrations as well, but the concentration at which these increases occurred varied among the donors. The results after 48 h and 6 d of exposure to PCP were similar to those seen after 24 h. Results from a representative experiment are shown in Fig. 1a . Table 3 shows the results of exposing PBMCs from four individual donors to 0-5 µM, PCP for 24, 48 h, and 6 d on the secretion of IL-1β. When PBMCs were exposed to PCP for 24 h, there were statistically significant increases in IL-1β secretion induced at 5 and 1 µM concentrations of PCP for all donors. The fold increases were 2.7 (F197), 2.2 (F211), 2.6 (F214), and 13 (F238) at 5 µM PCP compared to the secretion levels of the control after 24 h. The effects of 48-h and 6-d exposure to PCP were similar to those seen Figure 1b shows the results from a representative experiment at all three time points.
Effects of PCP exposures on secretion of IL-1β PBMCs
Effects of DDT exposures on secretion of IL-1β by NK cells
The results of exposing NK cells to 0, 0.025,.05 0.1, 0.25, 0.5, 1, and 2.5 µM DDT for 24, 48 h, and 6 d on the secretion of IL-1β are summarized in Table 4 . Twenty-four-hour exposures to DDT caused significant increases in IL-1β secretion from NK cells of three of the four donors, while the fourth donor was unaffected by exposures. However, after 48 h, the donor that had shown no significant increases in IL-1β secretion at 24 h now showed a 1.5-fold increase when exposed to 1 µM DDT. Thus, all donors showed an increase in IL-1β secretion after exposure to at least one concentration of DDT within 48 h. Table 5 shows the effects of exposing MD-PBMCs from four individual donors to 0-2.5 µM DDT for 24, 48 h, and 6 d on the secretion of IL-1β. Significant increases (twofold) in IL-1β secretion were shown in three donors, at 2.5 µM (F245, F281, F288 ). Significant decreases in IL-1β secretion were seen at several DDT concentrations in donor F287. At 48 h, all donors exhibited increased IL-1β secretion with exposure to at least on concentration of DDT. Sixday exposures to DDT showed effects similar to those seen at 48 h. Figure 2a shows the effects of 24-h, 48--h, and 6-d exposures of MD-PBMCs to DDT from a representative donor.
Effects of DDT exposures on secretion of IL-1β by MD-PBMCs
Effects of DDT exposures on secretion of IL-1β by PBMCs
The effects of exposing PBMCs from five individual donors to 0, 0.025, .05 0.1, 0.25, 0.5, 1, and 2. 5 µM DDT for 24, 48 h, and 6 d on the secretion of IL-1β are shown in Table 6 . At 48 h of exposure to DDT, all donors showed a significant increase in IL-1β secretion at the 2.5 µM concentration. Results from a representative donor are shown in Fig. 2b .
Effects of PCP exposures on secretion of IL-1βeta by PBMCS treated with selective enzyme inhibitors
NFκB inhibitor (BAY 11-7085)
The effects of exposures to 1, 2.5, and 5 µM PCP on secretion of IL-1β from PBMCs where NFκB was inhibited with BAY 11-7085 (0.325 µM) are shown in Table 7 . In some donors, inhibition of the NFκB pathway slightly increased the ability of PCP to stimulate IL-1β secretion from PBMCs and in other donors slightly decreased the effect of PCP. For instance cells from donor F317 show nine-, seven-, and threefold increases when PBMCs are exposed to 5, 2.5, and 1 µM PCP in the absence of the NFκB inhibitor. When the inhibitor is present PCP exposures result in seven-, five-, and onefold increases in IL-1β secretion. These results suggest that NFκB may play a small role in PCP's ability to stimulate the secretion of IL-1β by PBMCs. Data from a representative experiment are shown in Fig. 3a .
Mitogen activated protein kinase for ERK1/2 (MEK) inhibitor (PD98059)
PCP-induced stimulation of IL-1β secretion in PBMCs pretreated with the MEK inhibitor PD98059 (50 µM) is shown in Table 7 . Cells from all donors exposed to 5 μM PCP showed increases in IL-1β secretion. This PCP-stimulated secretion was diminished in each donor when the ERK1/2 pathway was inhibited by PD98059. There was a decrease in PCP-stimulated IL-1β secretion at 2.5 and 1 μM PCP in most donors For instance cells from donor F320 showed 10-, 7.6-, and 4.1-fold increases with 5, 2.5, and 1 μM in the absence of the MEK inhibitor. With the MEK inhibitor, these same concentrations of PCP caused increases of only 2.4-, 2.6-, and 1.6-fold. These results indicate that the ERK1/2 pathway may play a significant role in PCP's ability to stimulate secretion of IL-1β in PBMCs (Fig. 3b) .
p38 Inhibitor (SB202190)
Table 7 also shows the effects of exposures to 1, 2.5, and 5 µM PCP on secretion of IL-1β from PBMCs where p38 has been inhibited with SB202190. Inhibition of p38 tended to greatly decrease or completely block the PCP-induced increases in secretion of IL-1β. Figure 3c (representative data from F319) shows 2.5-, 1.8-, and 1.4-fold increases when PBMCs are exposed to 1, 2.5, and 5 µM PCP in the absence of p38 inhibitor. When the inhibitor is present, these same PCP exposures result in a complete block in IL-1β secretion. Thus, the p38 MAPK pathway appears to be very important in PCP-stimulated IL-1β secretion.
JNK inhibitor (BI78D3)
The effects of exposures to 1, 2.5, and 5 µM PCP on secretion of IL-1β from PBMCs where JNK is inhibited by BI78D3 (0.05 µM) are shown in Table 7 . Cells exposed to PCP showed similar levels of IL-1β secretion in the presence and absence of the JNK inhibitor. This indicates that JNK is not needed for PCP to increase IL-1β secretion from PBMCs (Fig. 3d) .
Caspase 1 inhibitor
The results of exposures to 1, 2.5, and 5 µM PCP on secretion of IL-1β from PBMCs where Caspase 1 has been inhibited by capase 1 inhibitor (0.325 μM) are shown in Table 7 . Inhibition of Caspase 1 had only minimal effects on PCP-induced IL-1β secretion. Figure 3e (representative data from F317) shows three-, four-, and fivefold increases when PBMCs are exposed to 1, 2.5, and 5 µM PCP in the absence of C1 inhibitor. When the inhibitor is present, these same PCP exposures result in 1.6-, 5.1-, and 3.2-fold increases in IL-1β secretion. These results suggest that Caspase 1 may play a small role in PCP's ability to stimulate secretion of IL-1β.
Discussion
Both PCP and DDT are found at significant level in human blood samples, with PCP being as high as 5 μM (Cline et al. 1989 ) and DDT as high as 260 nM (Koepke et al. 2004) . PCP exposure has been associated with kidney cancer, lymphoma, and myeloma (Demers et al. 2006) , while DDT exposure is linked to increased incidences of liver, pancreatic, breast, and testicular cancers as well as leukemia (Eskanazi et al. 2009; Cohn et al. 2007; Snedeker and Stapleton 2009) . Studies have shown that the tumor binding (Hurd et al. 2012; Hurd-Brown et al. 2013 ) and lysing function (Reed et al. 2004; Nnodu and Whalen 2008) of human NK lymphocytes as well as their expression of important cell-surface proteins (Hurd et al. 2012; Hurd-Brown et al. 2013 ) is decreased by ex vivo exposure to PCP and DDT. IL-1β in its role as a pro-inflammatory cytokine is a master regulator of the immune response (Sahoo et. al 2011; Dinarello 1996) . Dysregulation of its levels can lead to loss of immune competency (decreased levels) or chronic inflammation (increased levels) (Dinarello 1996; Braddock and Quinn 2004; Dinarello 2004) . The current study examined whether PCP and/or DDT exposure altered secretion of this important cytokine from increasingly complex preparations of human immune cells and results indicated that both compounds were able to increase IL-1β secretion dependent on length and concentration of the exposure. The immune cell preparations used in this study ranged from a preparation that was predominantly NK lymphocytes to PBMCs which were a combination of lymphocytes and monocytes. Additionally, a preparation of T and NK lymphocytes (MD-PBPMCs) was also examined. When these three cell preparations were exposed to PCP, Table 5 Effects of 24 h, 48 h, 6 day exposures to DDT on IL-1β secretion from MD-PBMCs there was no major effect on the viability of the immune cells, which indicated that the effects seen on IL-1β secretion were not due cell death. NK cells tended to show decreases in IL-1β secretion as the highest concentration of PCP (5 μM) and increases at lower concentrations (the specific concentration at which increases were seen varied among donors). However, when the more complex preparations (MD-PBMCs and PBMCs) were exposed to PCP there were increases in IL-1β secretion induced by the higher exposure concentrations after 24 h. For instance, all donors tested showed increases at the 5 μM concentration after 24 h in MD-PBMCs and at the 5-1 μM concentrations in PBMCs. In PBMCs, concentrations as low as 0.1 μM caused significant increases (approximately twofold) in secretion after either 24 or 48 h of exposure in cells from all donors, and the lowest concentration examined (0.05 μM) also caused significant increases in three of the four donors at one or more length of exposure. The highest fold increase seen with PCP exposure was 13-fold after a 24-h exposure to 5 μM PCP in PBMCs. Thus, all cell preparations tested showed alterations in IL-1β secretion in response to PCP exposures. However, preparations with T cells (MD-PBMCs) and with monocytes (PBMCs) had a different pattern of response than was seen with NK cells. This suggests that the more complex milieu of cells, that more closely approximates physiological conditions, responds to a wide range of PCP exposures by increasing secretion of the pro-inflammatory IL-1β.
DDT exposures caused the same general effect in all three cell preparations. NK cells, MD-PBMCs, and PBMCs from all donors showed significant increases in IL-1β secretion with exposures to one or more PCP concentration at one or more length of incubation. Increases tended to be approximately twofold and usually persisted out to 6 days of exposure. Increases most commonly occurred at the 2.5 μM exposure, but in some donors occurred at the lowest concentration of 0.025 μM.
Signaling pathways involved in regulating the release of IL-1β from immune cells include Caspase I, NFκB and MAPKs (ERK1/2, p38, and JNK) (Lopez-Castejon and Brough 2011; Gaestel et al. 2009 ). PCP caused very robust increases in IL-1β secretion from PBMCs, and thus, this PCP-induced secretion was examined for the involvement of the above-mentioned signaling pathways. The data indicated that Caspase 1, NFκB, and JNK played little to no role in the ability of PCP to stimulate IL-1β release from immune cells, while both ERK1/2 and p38 MAPK pathways appeared to be needed for the effect. For example, a fourfold increase in IL-1β secretion stimulated by 1 μM PCP was dropped to 1.6-fold when the ERK1/2 pathway was inhibited with PD98059. Likewise, inhibition of the p38 pathway resulted in a loss of PCP-induced IL-1β secretion. Previous studies on exposure to PCP have shown an association of PCP exposures with a number of cancers (Demers et al. 2006; Cooper and Jones 2008) and increased IL-1β has been shown to promote cancer development (Balkwill and Mantovani 2001; Coussens and Werb 2002) . Thus, if PCP has effects on IL-1β secretion in exposed individuals, similar to those seen with a complex ex vivo system, the increased risk of cancer might be at least in part due to its capacity to increase IL-1β levels.
Both PCP and DDT showed variations in their effects on IL-1β secretion (specific lengths and concentrations of exposure) that was donor dependent. The concept of personalized treatment of a number of diseases, most especially cancer (Madureira and de Mello 2014) has begun to evolve. The results from this study indicate that there may be individualized responses to these environmental toxicants, which may be important in assessing risk of a variety of conditions. Additionally, these results indicate that both PCP and DDT may have the capacity to induce "sterile inflammation" (a term used to describe inflammation occurring in the absence of a microorganism) (Chen and Nunez 2010) . The results of the current study indicate that concentrations of PCP and DDT that have been shown to occur in human blood (Cline et al. 1989; Uhl et al. 1986; Koepke et al. 2004; Trejo-Acevedo et al. 2009 ) lead to elevation of IL-1β ex vivo. Such "sterile inflammation" could worsen multiple sclerosis and rheumatoid arthritis (Lucas and Hohlfeld 1995; Choy and Panayi 2001) as well as lead to enhanced tumor development and progression (Lewis and Varghese 2006; Smith and Kang 2013) . The results of the current study indicate that decreasing the levels of exposure to these contaminants, resulting in accompanying decreases in blood levels, may be important in preventing potential increases in the pro-inflammatory cytokine, IL-1β. In summary, both PCP and DDT cause increased secretion of the seminal pro-inflammatory cytokine IL-1β from increasingly reconstituted preparations of immune cells. This increased secretion occurs at varying concentrations of the toxicants over several lengths of exposure with the effects varying among donors. The PCP-induced increases in IL-1β secretion (from PBMCs) are largely independent of Caspase 1, NFκB, and JNK signaling activity, but appear to require the p38 MAPK pathway. 
